Login / Signup

Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment-An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse.

P Joy HoAndrew SpencerPeter MolleeChristian E BryantAnoop K EnjetiNoemi HorvathBelinda E ButcherJudith TrotmanSimon GibbsDouglas E Joshua
Published in: Clinical lymphoma, myeloma & leukemia (2024)
reduction in involved SFLC at Cycle 2 Day 1 is an appropriate target for reducing the risk of dialysis in myeloma patients with RI; below this threshold patients may benefit from a change in therapy. While Cfz-dexamethasone achieved favorable renal and disease outcomes, toxicity can be significant in this vulnerable cohort.
Keyphrases